Environmental

BDX’s R&D intensity supports product stewardship and lower-resource innovation versus many medtech peers, though it is not clearly best-in-class on disclosed environmental metrics.

The company’s capital allocation to development can indirectly reduce environmental footprint through more efficient device design, but peer advantage is limited by sparse emissions disclosure.

No major environmental controversies are evident in the provided data, which supports a cleaner risk profile than peers with heavier manufacturing or supply-chain exposure.

Environmental positioning remains solid rather than leading because the available metrics emphasize innovation spending, not direct carbon, water, or waste performance versus peers.

Social

BDX’s core healthcare products support patient outcomes and access, giving it a structurally favorable social profile versus peers in less essential end markets.

The company’s sustained R&D investment indicates continued focus on product quality and clinical relevance, which typically strengthens trust and adoption relative to slower innovators.

Low stock-based compensation intensity suggests less dilution pressure on employees and shareholders, which can support a more balanced stakeholder model than peers with heavier equity pay.

Social risk remains moderate because the provided data do not show labor, safety, or supply-chain controversies, but peer-leading evidence on workforce metrics is limited.

Governance

BDX’s debt-to-equity ratio appears manageable, which supports governance discipline versus more levered peers and reduces pressure for short-term financial engineering.

Net debt to EBITDA is elevated but not extreme, indicating leverage is a monitored constraint rather than a clear governance weakness relative to peers.

Negative stock-based compensation to revenue suggests restrained equity dilution, which is generally more shareholder-aligned than peers with aggressive compensation structures.

Governance is solid overall, but the absence of detailed board, audit, and controversy disclosures in the provided data prevents a higher relative score.

Overall Score

BDX screens as a strong ESG name versus peers, led by favorable social positioning and disciplined governance, with environmental evidence less complete.

Score Driver: Essential Healthcare Exposure Combined With Disciplined Capital And Compensation Metrics